News
-
-
COMMUNIQUÉ DE PRESSE
Two Investigator-Initiated Responder Analysis Trials of Jaguar Health's Crofelemer Show Significant Positive Results for Chronic Refractory Diarrhea in IBS-D: Data Accepted for Presentation at American College of Gastroenterology 2024 Annual Meeting
Napo Pharmaceuticals announced positive results of studies on crofelemer for chronic refractory diarrhea at the ACG Annual Scientific Meeting. The drug may benefit patients with functional diarrhea and chronic idiopathic diarrhea -
COMMUNIQUÉ DE PRESSE
Berentzen-Gruppe Aktiengesellschaft publishes preliminary results for the first half of the year
Berentzen-Gruppe Aktiengesellschaft reports a 55% increase in consolidated operating profit (EBIT) to EUR 5.1 million for the first half of 2024, with significant growth attributed to profitability strategy and successful marketing -
COMMUNIQUÉ DE PRESSE
EQS-Adhoc: Berentzen-Gruppe Aktiengesellschaft: Group Half-Yearly Financial Report 2024 / Preliminary business figures as of June 30, 2024 / Update of the forecast for the 2024 financial year / Advanced negotiat
Berentzen-Gruppe Aktiengesellschaft expects increased profits for the first half of 2024, updates forecast for the year, and announces negotiations for the sale of a site in Non-alcoholic Beverages segment -
-
-
COMMUNIQUÉ DE PRESSE
Abasca Resources Provides Update on Summer Exploration Program at KLS Project and Restates Prior Results
Abasca Resources Inc. provides updates on its 2024 summer exploration program at the Loki Zone for Flake Graphite potential and uranium mineralization. Restated financial figures also disclosed -
COMMUNIQUÉ DE PRESSE
South Star Announces Successful Product Qualification and 100-Tonne Sale of Natural Flake Graphite Concentrate to U.S. Customer
South Star announces execution of a commercial sales agreement for graphite concentrate from its Santa Cruz Graphite Mine in Brazil, reinforcing its position as the first new natural-flake graphite mine in the Americas -
-
COMMUNIQUÉ DE PRESSE
enVVeno Medical Reports Second Quarter 2024 Financial Results and Provides Corporate Update
enVVeno Medical Corporation reported financial results and clinical program updates for Q2 2024, including positive VenoValve trial data and progress on enVVe valve launch. Cash balance of $39.1M to fund operations till 2025
